Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular and Cellular Oncology is Scopus-indexed (Q4, CiteScore 3), WoS ESCI, DOAJ. Published by Taylor and Francis Ltd..
Checked against the index lists dated .
ISSN 2372-3556Verify ISSN ↗
Publisher: Taylor and Francis Ltd.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cancer Research | 178 / 233 | 23rd | Q4 |
| Molecular Medicine | 140 / 179 | 22nd | Q4 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2014–present, best quartile Q4, CiteScore 3.
Molecular and Cellular Oncology is Q4 in Cancer Research (rank 178 of 233) and Q4 in Molecular Medicine (rank 140 of 179), by CiteScore 2025.
Molecular and Cellular Oncology is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3, which places it in quartile Q4 at the 23rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.620, quartile Q3, with an H-index of 39.
The publisher lists an article processing charge of about US$1,590 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular and Cellular Oncology is published by Taylor and Francis Ltd. Its ISSN is 2372-3556.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Molecular and Cellular Oncology has an h-index of 46 and a 2-year mean of 2.52 citations per paper (OpenAlex). Its Scopus CiteScore is 3, quartile Q4. On 2-year citations it ranks #119 of 229 Scopus journals in Cancer Research.
Molecular and Cellular Oncology published 11 papers in 2025; its busiest recent year was 2020 with 122. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 56 research articles (2021–2026), authors are most often from China (21.1%), United States (21%) and Japan (6.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.